American Association for Cancer Research Welcomes New Board of Directors, Nominating Committee Members

Get Permission

James P. Allison, PhD

Ronald M. Evans, PhD

Scott M. Lippman, MD

M. Celeste Simon, PhD

Joe W. Gray, PhD

Lillian L. Siu, MD

Margaret R. Spitz, MD, MPH

The members of the American Association for Cancer Research (AACR) have elected five members to serve on the AACR Board of Directors for the 2014–2017 term and four members to serve on the Nominating Committee for the 2014–2016 term. They assumed their roles at the AACR Annual Meeting 2014, held in San Diego, April 5–9.

Board of Directors

The following five scientists were elected to the AACR Board of Directors:

James P. Allison, PhD, is Chair of the Department of Immunology, Executive Director of the Immunology Platform, Associate Director of the Center for Cancer Immunology Research, Deputy Director of the David H. Koch Center for Applied Research in Genitourinary Cancer, and the Lilian H. Smith Distinguished Chair of Immunology at The University of Texas MD Anderson Cancer Center in Houston. He is a leader of the Stand Up To Cancer (SU2C)-Cancer Research Institute Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy.

Ronald M. Evans, PhD, is Professor at the Gene Expression Laboratory and March of Dimes Chair in Molecular and Developmental Biology at the Salk Institute for Biological Studies in La Jolla, California; Investigator with the Howard Hughes Medical Institute; and Adjunct Professor of Biology and Pharmacology at the University of California, San Diego (UCSD).

Scott M. Lippman, MD, is Director of the UCSD Moores Cancer Center; Senior Associate Dean and Associate Vice Chancellor for Cancer Research and Care at UCSD Health Sciences; Professor of Medicine and Chugai Pharmaceutical Chair in Cancer Research at UCSD; Adjunct Professor at the Salk Institute and the Sanford-Burnham Medical Institute in La Jolla; and Adjunct Professor at The University of Texas MD Anderson Cancer Center.

Guillermina Lozano, PhD, is Professor and Chair of the Department of Genetics, Co-Director of the Genetically Engineered Mouse Facility, Co-Director of the Center for Genetics and Genomics, Co-Director of the Sequencing and Microarray Facility, and Co-Director of the Cancer Genetics and Epigenetics Program at The University of Texas MD Anderson Cancer Center; and a member of The University of Texas Graduate School of Biomedical Sciences in Houston.

M. Celeste Simon, PhD, is Professor in the Department of Cell and Development Biology and Scientific Director and Investigator at the Abramson Family Cancer Research Institute, University of Pennsylvania in Philadelphia; and an investigator with the Howard Hughes Medical Institute.

Nominating Committee

The following four scientists were elected to the AACR Nominating Committee:

René Bernards, PhD, is Head of the Division of Molecular Carcinogenesis at the Netherlands Cancer Institute in Amsterdam; Professor of Molecular Carcinogenesis at Utrecht University in Utrecht, Netherlands; and founder and Chief Scientific Officer of Agendia BV in Amsterdam. He is a leader of the SU2C-Dutch Cancer Society (KWF Kankerbestrijding) Sta Op Tegen Kanker Translational Cancer Research Grant: Prospective Use of DNA-guided Personalized Cancer Treatment.

Joe W. Gray, PhD, is Gordon Moore Endowed Chair in the Department of Biomedical Engineering, Director of the Center for Spatial Systems Biomedicine, and Associate Director for Translational Research at the Knight Cancer Institute at Oregon Health & Science University in Portland; and a member of the graduate faculty and Professor in the Department of Radiation Medicine in the School of Medicine at Oregon Health and Science University. He is a leader of the SU2C Dream Team: An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and Their “Resistance” Phenotypes.

Lillian L. Siu, MD, is a Professor in the faculty of medicine at the University of Toronto in Toronto, Ontario; Director of the Drug Development Fellowship Program, Director of the Phase I Program, Co-Director of the Robert and Maggie Bras and Family Drug Development Program, and Staff Medical Oncologist at Princess Margaret Hospital in Toronto; and tier I Research Chair in Experimental Therapeutics at Cancer Care Ontario in Toronto.

Margaret R. Spitz, MD, MPH, is Professor at the Dan L. Duncan Cancer Center at Baylor College of Medicine in Houston. ■